🕒 Created

The Food and Drug Administration Approves Rasonque as a Groundbreaking New Treatment for Advanced Pancreatic Cancer

The Food and Drug Administration granted expedited approval for Rasonque (daraxonrasib), a once-daily pill designed to treat adults with metastatic pancreatic adenocarcinoma. This groundbreaking treatment targets mutated proteins that fuel tumor growth in more than 90% of pancreatic cancer cases, a driver that was previously considered "undruggable" for decades. In clinical trials, patients receiving Rasonque nearly doubled their median survival time, reaching 13.2 months compared to 6.7 months for those receiving standard chemotherapy. Revolution Medicines, the drugmaker, announced that a one-month supply of the medication will cost approximately $39,800. While the drug is not a cure, experts describe it as a significant improvement in quality of life and pain control. The administration announced the approval six months ahead of its target date, noting that the drug is now the new standard of care for patients who have received prior systemic therapy or are not candidates for multi-agent systemic therapy. Analysts project the drug may eventually expand into other cancer types, such as lung and colorectal cancer.

Sources